The system can transform the medical field by minimising blood damage and lowering associated costs. Credit: National Cancer Institute / Unsplash.

Inspira Technologies has secured a second US patent approval for its VORTX orbiting blood oxygenation delivery system, a key component of the INSPIRA ART device.

This approval brings the total number of new claims for the technology to 32.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The VORTX system is designed to oxygenate blood without the use of fibre membranes, which could revolutionise the medical field by reducing blood damage and associated costs.

Traditional fibre technologies for blood oxygenation can significantly damage blood cells, as they force blood through multiple fibre layers, creating turbulence, friction, and shear forces.

The high resistance of the fibre fabric to blood flow also creates pressure differences that can lead to severe blood component damage, including haemolysis, white blood cell damage, and blood clotting.

Inspira Technologies CEO Dagi Ben-Noon said: “We view this as another major leap forward in blood oxygenation technologies, representing another crucial milestone highlighting the core technological capabilities of the INSPIRA ART.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

INSPIRA ART is designed to support the 20 million patients in intensive care units with respiratory failure every year, a majority of whom depend on mechanical ventilators.

It helps maintain stable oxygen saturation levels without requiring ventilators.

Inspira Technologies OXY received approval from the Israeli Ministry of Health for its INSPIRA ART100 system in July 2024, marking a milestone in its efforts to commercialise its medical technology.

It also received 510(k) clearance from the US Food and Drug Administration (FDA) for cardiopulmonary bypass procedures and Israeli AMAR certification for both extra-corporeal membrane oxygenation and cardiopulmonary bypass procedures.

Inspira Technologies developed the INSPIRA ART with adaptive blood monitoring and oxygenation technology.

This system is designed to rebalance oxygen saturation levels in patients, potentially allowing them to remain awake during treatment and reducing reliance on invasive mechanical ventilation systems that necessitate intubation and medically induced coma.